{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:29:49Z","timestamp":1792020589195,"version":"4.4.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2019.01877","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T05:13:50Z","timestamp":1565673230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors"],"prefix":"10.3389","volume":"10","author":[{"given":"Micha\u0142 S.","family":"Barski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Minnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goedele N.","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1182\/blood-2010-02-270751","article-title":"Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.","volume":"116","author":"Afonso","year":"2010","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10580","DOI":"10.1128\/JVI.01799-15","article-title":"Viral source-independent high susceptibility of dendritic cells to human T-cell leukemia virus type 1 infection compared to that of T lymphocytes.","volume":"89","author":"Alais","year":"2015","journal-title":"J. Virol."},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-1-20","article-title":"Role of tax protein in human T-cell leukemia virus type-I leukemogenicity.","volume":"1","author":"Azran","year":"2004","journal-title":"Retrovirology"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/JVI.71.2.1025-1035.1997","article-title":"Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions.","volume":"71","author":"Balakrishnan","year":"1997","journal-title":"J. Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9210","DOI":"10.1128\/JVI.01164-10","article-title":"Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.","volume":"84","author":"Bar-Magen","year":"2010","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.leukres.2010.08.006","article-title":"Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia\/lymphoma.","volume":"35","author":"Beltran","year":"2011","journal-title":"Leuk Res."},{"key":"B7","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.2741\/1417","article-title":"Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression.","volume":"9","author":"Bindhu","year":"2004","journal-title":"Front. Biosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1093\/jpids\/piu070","article-title":"Mother-to-child transmission of human T-cell lymphotropic viruses-1\/2: what we know, and what are the gaps in understanding and preventing this route of infection.","volume":"3","author":"Carneiro-Proietti","year":"2014","journal-title":"J. Pediatr. Infect Dis. Soc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.sbi.2010.12.005","article-title":"Structural insights into the retroviral DNA integration apparatus.","volume":"21","author":"Cherepanov","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1093\/nar\/27.10.2202","article-title":"Activity of recombinant HIV-1 integrase on mini-HIV DNA.","volume":"27","author":"Cherepanov","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QAI.0000000000002065","article-title":"Is there a safety signal for dolutegravir and integrase inhibitors during pregnancy?","volume":"81","author":"Chouchana","year":"2019","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0236-7","article-title":"Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients.","volume":"13","author":"Cook","year":"2016","journal-title":"Retrovirology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12185-017-2361-7","article-title":"Long-term clinical remission maintained after cessation of zidovudine and interferon-alpha therapy in chronic adult T-cell leukemia\/lymphoma.","volume":"107","author":"Cook","year":"2018","journal-title":"Int. J. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/AID.2012.0132","article-title":"Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases.","volume":"29","author":"Demontis","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses."},{"key":"B15","doi-asserted-by":"publisher","first-page":"31186","DOI":"10.1074\/jbc.m704935200","article-title":"Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.","volume":"282","author":"Dicker","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006281","article-title":"Human T-lymphotropic virus type 1c subtype proviral loads, chronic lung disease and survival in a prospective cohort of indigenous australians.","volume":"12","author":"Einsiedel","year":"2018","journal-title":"PLoS Negl. Trop Dis."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002643","article-title":"Clinical associations of human T-lymphotropic virus type 1 infection in an indigenous australian population.","volume":"8","author":"Einsiedel","year":"2014","journal-title":"PLoS Negl. Trop Dis."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection.","volume":"3","author":"Gessain","year":"2012","journal-title":"Front. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1002\/phar.1478","article-title":"). Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV - an alternative viewpoint.","volume":"34","author":"Gillette","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1128\/JVI.73.10.8104-8111.1999","article-title":"Efficiency and fidelity of full-site integration reactions using recombinant simian immunodeficiency virus integrase.","volume":"73","author":"Goodarzi","year":"1999","journal-title":"J. Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/bioinformatics\/15.4.305","article-title":"ESPript: analysis of multiple sequence alignments in PostScript.","volume":"15","author":"Gouet","year":"1999","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00390","article-title":"Driving HIV-1 into a vulnerable corner by taking advantage of viral adaptation and evolution.","volume":"8","author":"Harada","year":"2017","journal-title":"Front. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature08784","article-title":"Retroviral intasome assembly and inhibition of DNA strand transfer.","volume":"464","author":"Hare","year":"","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.","volume":"107","author":"Hare","year":"","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","article-title":"Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.","volume":"116","author":"Iwanaga","year":"2010","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability.","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis.","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"B28","doi-asserted-by":"publisher","first-page":"15910","DOI":"10.1073\/pnas.1002346107","article-title":"Structure-based modeling of the functional HIV-1 intasome and its inhibition.","volume":"107","author":"Krishnan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood.V74.7.2596.2596","article-title":"Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men.","volume":"74","author":"Lairmore","year":"1989","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/sj.emboj.7601005","article-title":"Retroviral DNA integration: reaction pathway and critical intermediates.","volume":"25","author":"Li","year":"2006","journal-title":"EMBO J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0168-1702(01)00287-8","article-title":"The effect of antiretroviral therapy on HTLV infection.","volume":"78","author":"Machuca","year":"2001","journal-title":"Virus Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/nar\/gkv1347","article-title":"B\u2019-protein phosphatase 2A is a functional binding partner of delta-retroviral integrase.","volume":"44","author":"Maertens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nature09517","article-title":"The mechanism of retroviral integration from X-ray structures of its key intermediates.","volume":"468","author":"Maertens","year":"2010","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11899-007-0035-x","article-title":"Adult T-cell leukemia\/lymphoma and HTLV-1.","volume":"2","author":"Mahieux","year":"2007","journal-title":"Curr. Hematol Malig. Rep."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005560","article-title":"CADM1\/TSLC1 identifies HTLV-1-infected cells and determines their susceptibility to CTL-mediated lysis.","volume":"12","author":"Manivannan","year":"2016","journal-title":"PLoS Pathog."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1128\/jvi.74.20.9525-9531.2000","article-title":"In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy.","volume":"74","author":"Mansky","year":"2000","journal-title":"J. Virol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1021\/bi800791q","article-title":"Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.","volume":"47","author":"Marinello","year":"2008","journal-title":"Biochemistry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/s0140-6736(18)30974-7","article-title":"Time to eradicate HTLV-1: an open letter to WHO.","volume":"391","author":"Martin","year":"2018","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jns.2016.10.030","article-title":"HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): a comparative study to identify factors that influence disease progression.","volume":"371","author":"Matsuura","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/13550280152403272","article-title":"HTLV-I proviral load correlates with progression of motor disability in HAM\/TSP: analysis of 239 HAM\/TSP patients including 64 patients followed up for 10 years.","volume":"7","author":"Matsuzaki","year":"2001","journal-title":"J. Neurovirol."},{"key":"B41","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1097\/QAD.0000000000001992","article-title":"Elvitegravir\/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.","volume":"32","author":"Momper","year":"2018","journal-title":"AIDS"},{"key":"B42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1432-1327.1999.00026.x","article-title":"Characterization of human T-cell leukemia virus type I integrase expressed in Escherichia coli.","volume":"259","author":"Muller","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/13550289809114225","article-title":"Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM\/TSP.","volume":"4","author":"Nagai","year":"1998","journal-title":"J. Neurovirol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1016\/j.bmcl.2018.05.027","article-title":"The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor.","volume":"28","author":"Naidu","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B45","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archneur.63.11.1560","article-title":"Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study.","volume":"63","author":"Olindo","year":"2006","journal-title":"Arch. Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2005.05.010","article-title":"HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM\/TSP patients: a marker of disease progression.","volume":"237","author":"Olindo","year":"2005","journal-title":"J. Neurol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.1128\/jvi.02863-06","article-title":"Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate.","volume":"81","author":"Pandey","year":"2007","journal-title":"J. Virol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00278","article-title":"How to control HTLV-1-associated diseases: preventing de novo cellular infection using antiviral therapy.","volume":"9","author":"Pasquier","year":"2018","journal-title":"Front. Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1128\/AAC.01361-07","article-title":"Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication.","volume":"52","author":"Rabaaoui","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/QAI.0000000000001924","article-title":"Brief Report: surveillance of congenital anomalies after exposure to raltegravir or elvitegravir during pregnancy in the united kingdom and ireland, 2008-2018.","volume":"80","author":"Rasi","year":"2019","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006030","article-title":"T cell receptor vbeta staining identifies the malignant clone in adult T cell leukemia and reveals killing of leukemia cells by autologous CD8+ T cells.","volume":"12","author":"Rowan","year":"2016","journal-title":"PLoS Pathog."},{"key":"B52","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1073\/pnas.1018360108","article-title":"Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.","volume":"108","author":"Sampah","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B53","author":"Schrodinger","year":"2015","journal-title":"The PyMOL molecular graphics system, Version 1.8."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/AAC.01413-10","article-title":"Integrase inhibitors effective against human T-cell leukemia virus type 1.","volume":"55","author":"Seegulam","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-6-25","article-title":"Raltegravir, elvitegravir, and metoogravir: the birth of \u201cme-too\u201d HIV-1 integrase inhibitors.","volume":"6","author":"Serrao","year":"2009","journal-title":"Retrovirology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.","volume":"51","author":"Summa","year":"2008","journal-title":"J. Med. Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/13550280390173418","article-title":"Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis.","volume":"9","author":"Takenouchi","year":"2003","journal-title":"J. Neurovirol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1970","article-title":"Human T-lymphotropic virus type 1 infection and solid organ transplantation.","volume":"28","author":"Taylor","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/jac\/dkr404","article-title":"Antiviral effect of raltegravir on HTLV-1 carriers.","volume":"67","author":"Trevino","year":"2012","journal-title":"J. Antimicrob Chemother."},{"key":"B60","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a Novel Potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile.","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40262-018-0684-z","article-title":"Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps.","volume":"58","author":"van der Galien","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","article-title":"Jalview Version 2\u2013a multiple sequence alignment editor and analysis workbench.","volume":"25","author":"Waterhouse","year":"2009","journal-title":"Bioinformatics"},{"key":"B63","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/nejmc1809779","article-title":"Risk of human T-Cell leukemia virus type 1 infection in kidney transplantation.","volume":"380","author":"Yamauchi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/1346-8138.13004","article-title":"Human T-lymphotropic virus type I proviral loads in patients with adult T-cell leukemia-lymphoma: comparison between cutaneous type and other subtypes.","volume":"42","author":"Yonekura","year":"2015","journal-title":"J Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1056\/nejmc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception.","volume":"379","author":"Zash","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001705","article-title":"Living invisible: HTLV-1-infected persons and the lack of care in public health.","volume":"6","author":"Zihlmann","year":"2012","journal-title":"PLoS Negl. Trop Dis."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.01877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T14:19:34Z","timestamp":1664115574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.01877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":66,"alternative-id":["10.3389\/fmicb.2019.01877"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2019.01877","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"article-number":"1877"}}